Combined modality treatment of glioblastoma multiforme: the role of temozolomide.
Explore this paper's citation graph
Summary
The integration of the oral cytotoxic agent temozolomide into current treatment protocols of postoperative combination therapy with radiation and drugs is discussed, especially in the context of the recently published randomized trial of the EORTC/NCIC, which showed that radiotherapy plus concomitant and adjuvant temozoomide significantly improved progression-free and overall survival over radiotherapy alone.
- Type
- review
- Published
- 2006-01-01
- Cited by
- 25
- References
- 64
- OpenAlex
- https://openalex.org/W2073463500
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:27653536
Keywords
Temozolomide, Glioblastoma, Medicine, Treatment modality, Modality (human–computer interaction)
References
- Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients.
- Efficacy and Toxicity of Postoperative Temozolomide Radiochemotherapy in Malignant Glioma
- A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party.
- Concurrent Accelerated Hyperfractionated Radiation Therapy and Carboplatin/etoposide in Patients With Malignant Glioma: Long-term break Results of A Phase II Study
- Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.
- Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.
- Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine.
- Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
- DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.
- Response criteria for phase II studies of supratentorial malignant glioma.
- Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme.
- Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life.
- Temozolomide in the treatment of recurrent malignant glioma
- Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
- The Brain Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery, External Radiotherapy, and Carmustine versus Surgery, Interstitial Radiotherapy Boost, External Radiation Therapy, and Carmustine
- Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme.
- Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project.
- Survival of human glioma cells treated with various combination of temozolomide and X-rays.
- Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.
- Anti‐erbB receptor strategy as a gene therapeutic intervention to improve radiotherapy in malignant human tumours
Cited by
- The neural adhesion molecule L1CAM confers chemoresistance in human glioblastomas.
- Apport des nanocapsules lipidiques dans le traitement local des gliomes malins: application à l'encapsulation de complexes lipophiles métalliques
- Nanoparticle based strategies for the treatment of Glioblastoma
- CX3CR1 promotes recruitment of human glioma-infiltrating microglia/macrophages (GIMs).
- Reversing the Warburg Effect as a Treatment for Glioblastoma*
- Volumetric and MGMT parameters in glioblastoma patients: Survival analysis
- Lost in disruption: role of proteases in glioma invasion and progression.
- Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers
- Matrix Metalloproteinase-19 is Highly Expressed in Astroglial Tumors and Promotes Invasion of Glioma Cells
- Expression and role of the cell surface protease seprase/fibroblast activation protein-α (FAP-α) in astroglial tumors
- A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue
- Convection-enhanced delivery of nanocarriers for the treatment of brain tumors.
- MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma
- Radiotherapy using IMRT boosts after hyperbaric oxygen therapy with chemotherapy for glioblastoma
- Advances in Neurotherapeutic Delivery Technologies
- Outcomes of Treatment for Glioblastoma Multiforme in Adult Patients: A Single Institution Experience from the Eastern Black Sea Region of Turkey
- Benefit and outcome of using temozolomide-based chemoradiotherapy followed by temozolomide alone for glioblastoma in clinical practice.
- Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas
- Enhancing glioblastoma cytotoxicity through encapsulating O6-benzylguanine and temozolomide in PEGylated liposomal nanocarrier: an in vitro study
- A Review of Current Treatment Options for Glioblastoma Multiforme
Related papers
- The role of temozolomide in newly-diagnosed glioblastoma multiforme
- 42 A novel approach using accelerated hypo-fractionation-IMRT (AH-IMRT) and temozolomide (TMZ) in patients with glioblastoma multiforme (GBM)
- Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme
- 2. Glioblastoma再発に対しTemozolomideを使用した１例(第35回群馬脳腫瘍研究会)
- 12-Cycle of Temozolomide Treatment is not Superior To 6-Cycle of Treatment in Glioblastoma Multiforme
- Evaluation of tolerance of Temozolomide in different strategies for management of the older person with glioblastoma
- EP-1204: Limited margin radiotherapy and temozolomide for glioblastoma multiforme: pattern of failure
- Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?
- Utility of Dynamic Contrast-Enhanced (DCE) MRI in Predicting Prognosis of Enhancing Lesions Persisting after Completion of Adjuvant Temozolomide in Glioblastoma Patients